Modeling and simulation are routinely used in many other industries, yet their use in drug development has been limited. In the July issue of CPT, Richard L Lalonde et al. argue that broader implementation of MBDD will help address the “critical path” problem in drug development. In MBDD, modeling and simulation, which help predict the results of future drug trials, are used at each decision point in the drug development process to quantitatively assess the risk of moving forward. Thus, MBDD can improve the efficiency and reduce the costs of clinical drug development.

Read the article here.